Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis.

Background: Contrast agents directly cause kidney toxicity in patients who are candidates for percutaneous intervention having cardiovascular disease with type 2 diabetes.

Aims: This meta-analysis aims to assess the effects of SGLT2i on renal function in individuals undergoing percutaneous intervention.

Methods: The databases used for the search included Google Scholar, PubMed, Cochrane Central Registry of Controlled Trials, and Scopus. We considered randomized controlled and observational studies published from January, 2013, to August, 2023. Eligibility to include the studies was assessed independently. The Cochrane modified data extraction form and Joanna Briggs Institute were used to extract the data. The quality of the studies was evaluated using the Cochrane risk of bias tool and the Newcastle-Ottawa scale. The GradePro software was used to measure the certainty of the evidence.

Results: The pooled estimate showed a substantial reduction in serum creatinine levels at 48 and 72 hours post-PCI who received SGLT2i (MD -9.57; 95% CI -18.36, -0.78; p-value 0.03 and MD - 14.40; 95% CI -28.57, -0.22; p-value 0.05). There was a decrease in the occurrence of the CI-AKI among SGT2i users (RR: 0.46; 95% CI: 0.32, 0.67; p value< 0.0001). No substantial difference was observed in the number of patients requiring hemodialysis; however, a lower proportion of patients among SGLT2i users required hemodialysis (RR: 0.88; 95% CI: 0.19, 4.07; p-value = 0.87).

Conclusion: The use of SGLT2i confers substantial beneficial effects on kidney function and reduces the occurrence of contrast-induced acute kidney injury among diabetes patients undergoing PCI procedures with cardiovascular disease.